Chapters

Transcript

Video

What specific LDL-C-related endpoints are likely to undergo review and revisions based on the publication of two PCSK9-related trials, ODYSSEY Outcomes and FOURIER?

What specific LDL-C-related endpoints are likely to undergo review and revisions based on the publication of two PCSK9-related trials, ODYSSEY Outcomes and FOURIER?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Alberico Catapano, PhD

Alberico Catapano, PhD

Full Professor of Pharmacology

University of Milano

Director, Laboratory for the Study of Lipoproteins and Atherosclerosis

Director, Center for the Study of Atherosclerosis of the Italian Society of Atherosclerosis